Neocytolysis Contributes to the Anemia of Renal Disease by Driscoll, Theda et al.
.As -i 3o68
Neocytolysis Contributes to the
Anemia of Renal Disease
f_ _;:;"_"
,f .
Lawrence Rice, M.D.
Associate Professor of Medicine
Clarence P. Alfrey, M.D., Ph.D.
Professor of Medicine
Theda Driscoll, C.N.T.
Carl E. Whitley, M.T.
David Hachey, Ph.D.
Associate Professor
Wadi Suki, M.D.
Professor of Medicine
Baylor College of Medicine
Houston, Texas
https://ntrs.nasa.gov/search.jsp?R=19980000293 2020-06-16T01:41:14+00:00Z
2Abstract
Neocytolysis is a recently described physiologic process effecting selective
hemolysis of young red blood cells in circumstances of plethora. Erythropoietin
depression appears to initiate the process, providing rationale to investigate its
contributions to the anemia of renal disease. When erythropoietin therapy was
withheld, four of five stable hemodialysis patients demonstrated SlCr red cell survival
patterns indicative of neocytolysis--red cell survival was short in the first 9 days, then
normalized. Two of these patients received oral 13C-glycine and lSN-glycine and
showed pathologic enrichment of stool porphyrins by the most recently ingested
isotope when EPO therapy was held. This confirms selective hemolysis of newly-
released red cells. (One patient had chronic hemolysis by isotope studies of blood and
stool.) Thus, neocytolysis can contribute to the anemia of renal disease and explains
some unresolved issues about such anemia. One implication is the prediction that
intravenous bolus erythropoietin therapy is metabolically and economically inefficient
compared to lower doses given more frequently subcutaneously.
Introduction
We have uncovered a physiologic process that selectively hemolyzes the
youngest circulating red blood cells in situations of red cell excess and have named
this process "neocytolysis. "(_) Neocytolysis became manifest while studying
mechanisms underlying "spaceflight anemia," an adaptation of astronauts to acute
plethora in microgravity. (2) Observations on individuals acclimated to high altitude who
descend to sea level also suggest neocytolysis, and we are actively extending these
3observations to further elucidate the process. (_) Neocytolysis occurs in situations
where erythropoietin (EPO) secretion is suppressed, creating suspicion that the
process is initiated by a fall in EPO levels below a threshold. On descent from altitude,
low doses of subcutaneous EPO prevented a rapid adaptive fall in red cell mass,
further implicating low EPO levels in precipitating this process, c4>
Renal insufficiency presents a pathologic situation in which EPO is depressed.
We sought to determine whether neocytolysis is present in some patients with renal
insufficiency and contributes to their anemia. If so, important implications might extend
to optimizing therapy for the anemia of renal disease.
Methods.
From among 9 stable dialysis patients screened, five were selected for study
and gave informed consent. Patients were selected on the basis of no active infection
or inflammatory diseases, no iron deficiency based on serum ferritin levels, and low
baseline EPO levels (all less than 25 units/ml) (Ramco, Houston). These patients were
studied during regular EPO therapy (generally 50 iEkg/tiw SQ) and for at least 12 days
while EPO was held.
All patients had red cell labeled with 50 l_Ci _lCr and survival curves traced by
standard methods both on and off EPO. (s) Three patients were administered 1 gm oral
13C-glycine and lSN-glycine, one isotope during standard EPO therapy and one prior to
holding exogenous EPO. Serial stool specimens were collected and stercobilin was
isolated by ethanol, ether and chloroform extraction, <6)and a final thin layer
4chromatography step.c_ Specimens were frozen at -20°C until analyzed for 13C and lSN
O (8)by mass spectrosc py.
Results
The figure shows a typical patient S_Cr-red cell survival curve, with the slope steeper
during the first 9 days (off EPO) than after 9 days (EPO therapy resumed). For all five
patients, the survival curve slope for the first 9 days off EPO was - 2.24 days (SD 0.34)
and the subsequent slope was -1.12 days (SDO. 47). Survival is statistically shorter in
the first 9 days off EPO (p < .05).
In the 3 patients who received oral _3C-glycine and _s N-glycine, two had
abnormal enrichment of their stool with the isotope administered just before EPO was
held. The third patient showed abnormal stool enrichment by both isotopes. This
patient also had the shortest S_Cr-red cell survival and appears to have a chronic
hemolytic process.
Discussion
Neocytolysis has been observed with physiologic EPO suppression in
astronauts and in polycythemic individuals descending from high altitude, and it has
been prevented by administration of low doses of EPO. (14) This mandated the study of
a situation in which there is pathologic EPO suppression, the anemia of renal
insufficiency. When five dialysis patients with low baseline EPO had their EPO therapy
withheld, a pattern of neocytolysis emerged in four (the fifth showing a pattern of
chronic hemolytic anemia). S_Cr-red cell survival curves showed a statistically steeper
slope in the first nine days after EPO was held, a pattern consistent with neocytolysis.
5Stool porphyrins were studied in two of the four patients with a pattern of neocytolysis
and both showed selective abnormal stool enrichment of the isotope administered at a
time that only young red cells (neocytes) would be labeled. This confirms selective
hemolysis of young red cells when EPO is withheld.
The anemia of renal disease was long regarded multifactorial in most patients,
but the extraordinary clinical efficacy of recombinant erythropoietin clearly establishes
erythropoietin deficiency as paramount.(9)Too quickly disregarded are studies
demonstrating a consistent hemolytic component of variable degree in the anemia of
renal insufficiency, (1°12}an extracorpuscular hemolytic component never fully
explained.<13) Neocytolysis can explain this hemolytic component without negating the
therapeutic efficacy of erythropoietin; after all, prevention of neocytolysis appears as a
newly-recognized action of erythropoietin. (4) Further support for this concept comes
from Eschbach's observation that erythropoietin therapy prolongs red cell survival in
renal diseases. (14)
Neocytolysis predicts inefficiency of intravenous bolus dosing schedules of
recombinant erythropoietin. The erythropoietin peak would effect commitment and
proliferation of erythroid progenitors, but the nadir would bring neocytolysis of newly-
released red cells. Neocytolysis might better explain the metabolic toxicities of
hyperkalemia and hyperphosphatemia that have been observed with bolus
erythropoietin therapy. (9) Quite a number of empiric studies have shown that
subcutaneous erythropoietin injections are more effective then intravenous boluses at
considerably lower total doses and cost. (_s°_e Investigators have been unable to
6satisfactorily explain the basis of this phenomenon, but avoidance of nadirs which
precipitate neocytolysis explain it nicely.
In summary, neocytolysis is a physiologic process allowing rapid adaptation to
plethora by selectively hemolyzing young red blood cells, apparently precipitated by
EPO depression. We now demonstrate its occurrence in four of five studied dialysis
patients. In the anemia of renal disease, neocytolysis helps to explain the (1) often
demonstrable hemolytic component, (2) worse hemolysis with more advanced renal
disease,_11)(3) responsiveness of hemolysis to erythropoietin therapy, (4) metabolic
side-effects of intravenous bolus erythropoietin, and (5) increased efficiency of daily
subcutaneous erythropoietin. Having shown that neocytolysis can contribute to anemia
in renal failure patients with low EPO baselines and not on active therapy, we are
launching studies of the intensity of neocytolysis in patients on intravenous bolus
versus low-dose daily subcutaneous erythropoietin therapy.
7References
o Alfrey CP, Rice L, Udden M, and Driscoll T: Neocytolysis: A physiologic down-
regulator of red blood cell mass. Lancet, 349:1389-90, 1997.
. Alfrey CP, Udden MM, Leach-Huntoon CS, et al.: Control of red blood cell mass
in spaceflight. J Appl Physiol, 81(1):98-104, 1996.
. Rice L, Udden M, Driscoll T, Whitley C, and Alfrey CP: Neocytolysis in the
adaptation of red cell mass on descent from altitude. Acta Andina, 1997, in
press.
. Rice L, Alfrey C, Ruiz W, Driscoll T, Whitley C and Gonzales G: Neocytolysis
on descent from altitude. Abstract submitted to American Society of
Hematology, 1997 (full manuscript in preparation).
. International Committee for Standardization in Haematology: Recommended
method for radioisotope red cell survival studies. Brit J Haematol, 45:659-666,
1980.
. Rothuizen J, van den Brom WE, and Fevery J: The origins and kinetics of
bilirubin in healthy dogs, in comparison with man. J Hepatology, 15:25-34,
1992.
o Samson D, Halliday D, Nicholson DC and Chanarin I. Quantitation of ineffective
erythropoiesis from the incorporation of [15N]delta-aminolaevulinin acid and
[13C]glycine into early labeled bilirubin. Brit J Haematol, 34:33-44, 1976.
. Labbe RF, Nishida G: A new method of hemin isolation. Biochemica et
Biophsica Acta 26:437, 1957.
° Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-
stage renal disease with recombinant human erythropoietin. N Engl J Med
316:73, 1987.
10. Eschbach JW, Funk D, Adamson JW, et al: Erythropoiesis in patients with renal
failure undergoing chronic dialysis. N Engl J Med 276:653, 1967.
11. Shaw AB: Haemolysis in chronic renal failure. Br Med J 2:213, 1967.
12. Adamson JW, Eschbach J, Finch Ca: The kidney and erythropoiesis. Blood
44:725-33, 1968.
13. Caro J, Erslev A J: Anemia of chronic renal failure. Williams, ed., 5th Edition,
pp 456-462, 1995.
814. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the
effects of recombinant erythropoietin. Kidney Int. 35:134-148, 1989.
15. Granolleras C, Branger B, Shaldon S, et al. Subcutaneous erythropoietin: a
comparison of daily and thrice weekly administration. Contrib Nephrol 88:144-
48, 1991.
16. Paganini EP, Eschbach JW, Lazarus JM, et al: Intravenous versus
subcutaneous dosing of epoetin alpha in hemodialysis patients. Am J Kidney
Dis, 26:331-340, 1995.
,.q >_
._q :-
C) C)
13 ©
j
C> C) C> C_ C>
fD C_ Do F--
- c,4
C)
C>D
-- C>
I i
C) C_ C>
.=
5_
O -
:> _ .-..I"
_jZcq
L) J.J ¢"_ f',
-,q .,q :>_ I
I izl _ _
. .iJ 'ii_I
